Eltenac, a new anti-inflammatory and analgesic drug for horses: clinical aspects.
Two controlled studies to determine efficacy in the horse were performed with eltenac, a new injectable, non-steroidal anti-inflammatory drug (NSAID). Clinical trials were carried out with a dose rate of 1 mg/kg body weight in a randomized, placebo-controlled, double-blind design to assess therapeutic efficacy in acute inflammatory disorders and in animals with orthopaedic conditions. In a preliminary pharmacokinetic investigation in six horses mean elimination half-life was 1.7 h after i.v. administration. In the first clinical study, analgesic activity on pain-related lameness was determined in a total of 64 horses. Pain was assessed using a rating scale. Compared with the placebo treatment, eltenac produced significant pain relief after a single i.v. injection for a period of 24 h. In the second trial the anti-oedematous effect was determined in post-operative wound swelling following castration in two groups of 10 colts. After surgery, the horses received either an injection of 1 mg/kg eltenac or a placebo injection on three consecutive days. Swelling was assessed by measuring the diameter of the external preputial fold using two methods: callipers and a rating scale of 0 to 3. Additionally, photographs were taken on days 1, 2 and 4. Compared with the placebo treatment, eltenac inhibited pain and swelling significantly. The effect was maintained for up to 48 h after the last injection.